Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT04165083
Brief Title: KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC ) (MK-3475-01B/KEYMAKER-U01B)

First Submitted : November 14, 2019
First Submitted that Met QC Criteria : November 14, 2019
First Posted : November 15, 2019

Last Update Submitted that Met QC Criteria : August 25, 2021
Last Update Posted : August 26, 2021